Recently, the Hangzhou Municipal Science and Technology Bureau issued the Announcement on the Proposed List of Hangzhou Enterprise High-tech R&D Centers in 2021. According to the Measures for Administration of Hangzhou Enterprise High-tech R&D Centers (HKJ No. 21 [2019]) and the Notice on Organizing the Application for Hangzhou Enterprise High-tech R&D Centers in 2021 (HKG No. 30 [2021]), Bioeast Biotech has been accredited as the Hangzhou Enterprise High-tech R&D Center in 2021 after the on-site inspection and evaluation by experts from the Hangzhou Municipal Science and Technology Bureau.

This event is mainly aimed at high-tech enterprises recognized by the science and technology management departments at or above the municipal level, and the investment of such enterprises in scientific and technological innovation and independent technology research and development is used as an important criterion of selection.

Bioeast Biotech has been selected as a Municipal Enterprise High-tech R&D Center for IVD Core Raw Materials, which fully shows that we are qualified as a high-tech enterprise with our R&D strength and technological innovation ability in the field of biological raw materials. 

Since our establishment, we have always adhered to the philosophy of integrity, efficiency, innovation, and excellence, concentrated on the construction of the R&D team, and gradually improved the experimental conditions and facilities for independent R&D and achievement transformation, growing into a global total solution provider of biomedical core raw materials.

In the future, we will continue to serve the global biological industry by giving full play to our advantages as a technology R&D center. We will further strengthen the construction of the R&D center, accelerate the transformation of R&D achievements, and continuously improve our R&D and innovation capabilities, striving to make contributions to the high-quality development of the regional economy.